الولايات المتحدة · منصات وبيانات · Morningstar

Akamis Bio to Present Data from a Phase 1 Study of NG-348 in Patients with Advanced Epithelial Tumors at SITC 2026

نشره Morningstar · الولايات المتحدة منذ 19 س

Akamis Bio to Present Data from a Phase 1 Study of NG-348 in Patients with Advanced Epithelial Tumors at SITC 2026 Akamis Bio, a clinical-stage oncology company working to advance…

اقرأ المقال كاملًا على Morningstar سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.morningstar.com)

يستحق القراءة أيضًا

Seeking Alpha

Renew outlines FY2027 adjusted EBITDA guidance of INR 105B to INR 109B as take-private process targets Q1 2027 close

MarketBeat

Energy Vault (NRGV) Set to Post Quarterly Earnings on Tuesday

MarketWatch

Want to help your adult kids and grandkids? Give them money while you’re still alive.

The Motley Fool

Where Will QuantumScape Stock Be in 5 Years?

Investing.com

Regal Rexnord Q3 2026 slides: organic growth accelerates to 6.1%

CNBC